IL-PROJECT44
17.10.2018 09:02:30 CEST | Business Wire | Press release
project44 (p44) and Gatehouse Logistics jointly announced today that they have entered into an exclusive, multinational agreement which will provide secure and authorized access to the largest visibility network across North America and Europe. Ultimately, accelerating the ability for both technology providers to deliver visibility solutions across multiple transportation modes and geographies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005211/en/
End-to-end supply chain visibility is critical for complex global organizations looking to monitor global operations, increase efficiencies and improve the overall customer experience. This first of its kind multinational partnership provides visibility into key transportation processes, ensuring global organizations can accurately see and proactively respond to all events in their supply chain at the “speed of thought.”
Gatehouse Logistics CEO Jesper Bennike commented that, “project44 and Gatehouse Logistics have been championing the importance of high-fidelity data for years. This collaboration aligns with both company’s core promise to deliver the most comprehensive global visibility engine powered only by secure, high-quality and real-time information.”
Since 1992, Gatehouse Logistics has been leading the way in securely sharing data across the supply chain, bringing with it much-needed visibility of inbound and outbound logistics. ghTrack is a GDPR compliant, neutral and hardware agnostic data sharing service enabling Gatehouse Logistics to build the largest network of telematics systems across Europe. Similarly, project44 has quickly become the leader in North American advanced visibility by building the largest and most inclusive network of capacity providers connected via ELD, telematics, direct API connections, app-less tracking, or smartphone applications.
With this partnership, customers of project44 and Gatehouse Logistics now have immediate and actionable access to a network of 175,000 multimodal carriers - comprised of 90,000 capacity providers in North America and 85,000 in Europe. Implementation processes have also been expedited to ensure fast and frictionless onboarding for all customers and rapid time-to-value.
“Visibility is the number one supply chain initiative. We’ve seen a record number of North American and European companies investing in real-time visibility platforms to be used either stand-alone or with a TMS, CRM, WMS or ERP,” said project44 founder and CEO Jett McCandless. “This partnership accelerates the speed at which manufacturers, retailers, ecommerce providers, distributors, freight forwarders, and 3PLs can successfully realize the benefits of end-to-end visibility by working with a single visibility provider for all shipments regardless of geographic location.”
To learn more about this exclusive partnership or schedule a demo, visit https://get.project44.com/ghl-partnership/ . Executive leaders from project44 and Gatehouse Logistics will be attending the 35th International Supply Chain Conference in Berlin (October 17-19, 2018) hosted by BVL. Editors attending the BVL Conference are invited to a reception in Gartenlounge II at 14:00 on October 17 for an exclusive briefing.
About project44:
project44 is the world’s leading advanced visibility platform for shippers and third-party logistics firms. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations are able to increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to over 175,000 carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. To learn more, visit www.project44.com .
About GateHouse Logistics A/S:
GateHouse Logistics is the brand owner of ghTrack, a completely neutral and independent cloud-based data sharing service that is leading the way business-critical data is securely shared across the entire supply chain. It is also the perfect foundation for emerging smart industries including IoT developments. ghTrack brings long-wanted, real-time end-to-end visibility to all stakeholders in the supply chain. It aggregates position and sensor data from all modes of transportation and presents them as one unified and logical data stream for simple integration into any business system. ghTrack is Europe’s most widely used, secure and GDPR compliant data sharing service. Visit www.ghTrack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005211/en/
Contact:
North American Media Contact: project44 Ally Lynch, VP Marketing Phone: 1-312-300-4899 Email: ally@project44.com or European Media Contact: GateHouse Logistics Mette Lilkær, Strategic Sales & Marketing Manager Landline: + 45 7020 1909. Mobile + 45 2920 2383 Email: mdl@gatehouse.dk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom